Aimei Health Technology Co., Ltd filed a Form 8-K on November 17, 2026, disclosing that on November 14, 2026, it entered into a non-binding letter of intent to pursue a business combination with Hera Health Solutions Inc., a Tennessee-based pharmaceutical technology company.

Key Highlights

  • Non-binding LOI signed: Aimei Health Technology and Hera Health Solutions Inc. entered into a non-binding letter of intent on November 14, 2026, for a proposed business combination.
  • Structure of the deal: Under the LOI terms, the Company would acquire 100% of Hera's outstanding equity and equity equivalents in exchange for shares of the combined public company.
  • Hera's technology focus: Hera Health Solutions is described as a pharmaceutical technology company developing drug delivery solutions using proprietary biodegradable nanofiber scaffold technology, electrospinning manufacturing, and its Hercules AI platform.
  • Binding provisions: The LOI is non-binding regarding the transaction itself, except for certain provisions including those relating to confidentiality and exclusivity.
  • No assurance of completion: According to the filing, "there can be no assurance that any definitive agreement will be executed or that the Proposed Transaction will be consummated."
  • Regulatory path outlined: If a definitive agreement is executed, the Company intends to file a registration statement on Form F-4 or Form S-4 with the SEC, which will include a proxy statement and prospectus.

Aimei Health's Proposed Combination With Hera Health Solutions

Aimei Health Technology Co., Ltd (NASDAQ:AFJK), a blank check company incorporated as a Cayman Islands exempted company and organized for the purpose of effecting a business combination, disclosed in an Item 7.01 Regulation FD filing that it has signed a non-binding letter of intent with Hera Health Solutions Inc. The event date reported is November 14, 2026. Hera is described in the filing as a Delaware corporation headquartered in Memphis, Tennessee.

According to the filing, Hera's platform centers on biodegradable nanofiber scaffold technology and an advanced electrospinning manufacturing system, which are designed to reformulate existing medicines into long-acting implants, patches, and other sustained-release formats. The filing also describes Hera's Hercules AI technology as designed to accelerate formulation development and optimize drug release across therapeutic areas including women's health, infectious diseases, pain management, and metabolic disorders.

The filing states that the proposed transaction remains subject to negotiation and execution of definitive agreements, completion of due diligence, receipt of required regulatory and shareholder approvals, and satisfaction of other customary closing conditions. The Company noted it expects to announce additional details upon execution of a definitive business combination agreement. All forward-looking statements in the filing are the Company's own and are subject to its cautionary language regarding known and unknown risks and uncertainties.

What Was Disclosed

Aimei Health Technology disclosed the signing of a non-binding LOI on November 14, 2026, to combine with Hera Health Solutions Inc. through a share-based acquisition of 100% of Hera's equity. No definitive agreement has been executed and no closing conditions have been satisfied.